Tenofivir alafenamide (Altaeda, Alfida)
Tenofivir alafenamide
Cipla Medpro (Pty) Ltd
Registration
- Applicant
- Cipla Medpro (Pty) Ltd
- Certificate holder
- Cipla Medpro (Pty) Ltd.
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Altaeda EACH TABLET CONTAINS DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg EMTRICITABINE 200,0 mg TENOFOVIR ALAFENAMIDE FUMARATE EQUIVALENT TO TENOFIVIR ALAFENAMIDE 25,0 mg | 50 mg, 200 mg, 25 mgTablet | 55045555/20.2.8/0455Approved 4 July 2023 | Registered | Not determined | PIPIL |
| Alfida EACH TABLET CONTAINS DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg EMTRICITABINE 200,0 mg TENOFOVIR ALAFENAMIDE FUMARATE EQUIVALENT TO TENOFIVIR ALAFENAMIDE 25,0 mg | 50 mg, 200 mg, 25 mgTablet | 550456.45555/20.2.8/0456.455Approved 4 July 2023 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.